CoChat

A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

Betts, Robert F., Nucci, Marcio, Talwar, Deepak, Gareca, Marcelo, Queiroz‐Telles, Flavio, Bedimo, Roger J., Herbrecht, Raoul, Ruiz‐Palacios, Guillermo, Young, Jo‐Anne H., Baddley, John W., Strohmaier, Kim M., Tucker, Kimberly A., Taylor, Arlene F., Kartsonis, Nicholas A., Caspofungin High‐Dose Study Group · 2009 · Clinical Infectious Diseases

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing regimen. METHODS: Patients with proven invasive candidiasis were randomized to receive a standard or high-dose (150 mg/day) caspofungin treatment regimen. Safety was assessed in all patients as treated. Efficacy was assessed as a secondary objective in a full-analysis-set population. A favorable overall response was defined as symptom resolution and microbiological clearance at the end of caspofungin therapy. RESULTS: A total of 204 patients were included in the safety analysis (104 received the standard regimen, and 100 received the high-dose regimen), and 197 were included in the efficacy analysis (102 and 95 in the standard and high-dose treatment groups, respectively). Patient demographic characteristics, neutropenia status (6.7% and 8.0% had neutropenia, respectively), and Acute Physiology and Chronic Health Evaluation II scores (mean, 16.5 and 17, respectively) were similar between treatment groups. Significant drug-related adverse events occurred in 1.9% of patients receiving the standard regimen and 3.0% of patients receiving the high-dose regimen (difference, 1.1%; 95% confidence interval, -4.1% to 6.8%). The most-common drug-related adverse events in the standard and high-dose treatment groups were phlebitis (3.8% and 2.0%, respectively), increased alkaline phosphatase level (6.9% and 2.0%, respectively), and increased aspartate transaminase level (4.0% and 2.0%, respectively). Overall, 71.6% of patients who received the standard regimen and 77.9% of patients who received the high-dose regimen had favorable overall responses (difference, 6.3%; 95% confidence interval, -5.9% to 18.4%; not statistically significant). Mortality at 8 weeks after therapy was similar between groups. CONCLUSIONS: Both caspofungin dosing regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.

Overview

Integrity signals

Registry

Crossref · 10.1086/598933

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 17 references

Cited by

Metadata

Authors
Betts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., Strohmaier, K. M., Tucker, K. A., Taylor, A. F., Kartsonis, N. A., & Caspofungin High‐Dose Study Group
Affiliations
  • University of Rochester (US)
  • Lehigh Valley Hospital (US)
  • VA North Texas Health Care System (US)
  • Hôpitaux Universitaires de Strasbourg (FR)
  • University of Minnesota (US)
  • University of Alabama at Birmingham (US)
Corresponding author
Kartsonis, Nicholas A.
Venue
Clinical Infectious Diseases
Published
2009-06-15
Volume
48
Issue
12
Pages
1676-1684
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2168334830
Cited by
214
References
17
Citations by year
2026: 4 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 13 · 2019: 10 · 2018: 11 · 2017: 11 · 2016: 11 · 2015: 12 · 2014: 6 · 2013: 17 · 2012: 19
FWCI
17.85
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
caspofungin, invasive candidiasis, antifungal therapy, drug safety, drug-related adverse events, microbiological clearance, treatment efficacy, phlebitis, liver enzymes, mortality, neutropenia, adult patients, echinocandins, fluconazole, amphotericin B
MeSH terms
Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Alkaline Phosphatase, Antifungal Agents, Aspartate Aminotransferases, Candidiasis, Double-Blind Method, Female, Humans, Male, Middle Aged, Phlebitis, Treatment Outcome, Echinocandins, Lipopeptides, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.